文献速递其他结缔组织病

基线绝对单核细胞计数可预测系统性硬化症相关间质性肺病患者的肺功能下降:focuSSced 试验的事后分析

Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
PubMed 文献 · Semin Arthritis Rheum · 2024-01-14

本研究为 focuSSced 试验的事后分析,纳入 136 例系统性硬化症相关间质性肺病(SSc-ILD)患者,接受托珠单抗 162 mg 或安慰剂皮下注射每周一次共 48 周。安慰剂组基线绝对单核细胞计数(AMC)与 48 周用力肺活量(FVC)变化呈显著负相关(多变量校正 β=-0.573,95%CI -1.086 至 -0.060,P=0.029),托珠单抗组无显著关联。作者认为 AMC 可能是 SSc-ILD 疾病进展的生物标志物,尤其见于循环炎症标志物升高的早期 SSc 患者,并建议在其他 SSc-ILD 队列中验证。

要点

  • 在 focuSSced 试验安慰剂组中,基线 AMC 与 48 周 FVC 变化呈显著负相关(校正 β=-0.573,95%CI -1.086 至 -0.060)。
  • 在托珠单抗组中,基线 AMC 与 48 周 FVC 变化无显著关联。
  • 作者认为 AMC 可能是 SSc-ILD 疾病进展的生物标志物,尤其见于循环炎症标志物升高的早期 SSc 患者。

核心结论

  • AMC 可能是 SSc-ILD 疾病进展的生物标志物,尤其见于循环炎症标志物升高的早期 SSc 患者,并建议在其他 SSc-ILD 队列中验证。

研究设计与样本

  • focuSSced 试验的事后分析,该试验为多中心、双盲、随机、安慰剂对照试验,纳入病程≤60 个月的弥漫性皮肤型 SSc 成人患者。
  • 受试者接受托珠单抗 162 mg 或安慰剂皮下注射每周一次共 48 周。
  • 本研究纳入 focuSSced 中 136 例 SSc-ILD 患者,采用校正潜在混杂因素的通用线性模型分析基线 AMC 与 48 周 FVC 的关系。

主要发现

  • 安慰剂组基线 AMC 与 48 周 FVC 自基线变化呈显著负相关:未校正模型 β 系数 -0.539(95%CI -1.032 至 -0.047,P=0.032),多变量校正模型 β 系数 -0.573(95%CI -1.086 至 -0.060,P=0.029)。
  • 托珠单抗组基线 AMC 与 48 周 FVC 自基线变化在未校正或完全校正模型中均无统计学显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些结果应在其他 SSc-ILD 队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) is the leading cause of death in adults with systemic sclerosis (SSc). The identification of biomarkers to predict progression of SSc-ILD is an important unmet need. The purpose of this study was to determine whether an elevated baseline absolute monocyte count (AMC) is associated with a decline in forced vital capacity (FVC) at 48 weeks among participants with SSc-ILD enrolled in the phase 3 focuSSced trial. METHODS: We performed a post-hoc analysis of the focuSSced trial, a multicenter, double-blind, randomized, placebo-controlled trial of adults with diffuse cutaneous SSc for ≤ 60 months. Participants received subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks. We examined the relationship between baseline AMC and FVC at 48 weeks using a General Linear Model adjusted for potential confounders. RESULTS: The 136 participants with SSc-ILD in focuSSced were included in this study. Among participants assigned to the placebo group, there was a statistically significant inverse association between baseline AMC and change in FVC from baseline at week 48 in both unadjusted (β coefficient -0.539, 95 % CI -1.032 to -0.047, p-value=0.032) and multivariable-adjusted (β coefficient -0.573, 95 % CI -1.086 to -0.060, p-value=0.029) models. Among participants with SSc-ILD assigned to the tocilizumab group, there was no statistically significant association between baseline AMC and change in FVC from baseline at week 48 in unadjusted or fully adjusted models. CONCLUSION: AMC may be a biomarker of disease progression in SSc-ILD, especially in those with early SSc with elevated circulating inflammatory markers. These results should be validated in other SSc-ILD cohorts.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Bernstein EJ, Denton CP, Huang S, et al. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial. Semin Arthritis Rheum. 2024. PMID: 38244446. doi:10.1016/j.semarthrit.2024.152376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。